Meeting
2011 ASCO Annual Meeting
Survival after nonmyeloablative versus myeloablative allotransplantation for AML/MDS.
Authors
M. R. Khawaja
Indiana University School of Medicine and the IU/Melvin and Bren Simon Cancer Center, Indianapolis, IN
M. R. Khawaja , J. E. Schwartz , M. Yu , M. J. Robertson , G. H. Vance , S. Srivastava , L. L. Wood , R. Abonour , K. Cornetta , S. Farag , L. D. Cripe , R. P. Nelson Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Allogeneic Bone Marrow
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6563)
Abstract #
6563
Poster Bd #
33H
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.
First Author: Uday R. Popat
Poster
2012 ASCO Annual Meeting
Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome.
First Author: Henry Jacob Conter
Poster
2011 ASCO Annual Meeting
A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen.
First Author: S. Kim
Poster
2023 ASCO Annual Meeting
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
First Author: Jian-Qing Mi